148 related articles for article (PubMed ID: 25002124)
21. Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.
Varzavand A; Drake JM; Svensson RU; Herndon ME; Zhou B; Henry MD; Stipp CS
Clin Exp Metastasis; 2013 Apr; 30(4):541-52. PubMed ID: 23224938
[TBL] [Abstract][Full Text] [Related]
22. Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth.
Jeong KC; Kim KT; Seo HH; Shin SP; Ahn KO; Ji MJ; Park WS; Kim IH; Lee SJ; Seo HK
J Urol; 2014 Feb; 191(2):510-8. PubMed ID: 23872029
[TBL] [Abstract][Full Text] [Related]
23. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
24. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer.
Kuwada M; Chihara Y; Luo Y; Li X; Nishiguchi Y; Fujiwara R; Sasaki T; Fujii K; Ohmori H; Fujimoto K; Kondoh M; Kuniyasu H
Cancer Lett; 2015 Dec; 369(1):212-21. PubMed ID: 26342407
[TBL] [Abstract][Full Text] [Related]
25. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
26. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.
Fan J; Stanfield J; Guo Y; Karam JA; Frenkel E; Sun X; Hsieh JT
Clin Cancer Res; 2008 Feb; 14(4):1200-7. PubMed ID: 18281555
[TBL] [Abstract][Full Text] [Related]
27. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
29. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo.
Sun F; Zheng XY; Ye J; Wu TT; Wang Jl; Chen W
Nutr Cancer; 2012; 64(4):599-606. PubMed ID: 22482362
[TBL] [Abstract][Full Text] [Related]
30. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
32. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
33. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.
Garrido G; Rabasa A; Garrido C; López A; Chao L; García-Lora AM; Garrido F; Fernández LE; Sánchez B
Oncogene; 2014 Jun; 33(24):3129-39. PubMed ID: 23975426
[TBL] [Abstract][Full Text] [Related]
34. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
36. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.
Singh RP; Tyagi A; Sharma G; Mohan S; Agarwal R
Clin Cancer Res; 2008 Jan; 14(1):300-8. PubMed ID: 18172282
[TBL] [Abstract][Full Text] [Related]
37. MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.
Zhu Y; Jiang H; Zhang C; He QJ; Yang B; Li LJ; Zhu H
Pharmazie; 2009 Dec; 64(12):823-8. PubMed ID: 20095141
[TBL] [Abstract][Full Text] [Related]
38. Differences of alpha3beta1 integrin glycans from different human bladder cell lines.
Lityńska A; Przybyło M; Ksiazek D; Laidler P
Acta Biochim Pol; 2000; 47(2):427-34. PubMed ID: 11051207
[TBL] [Abstract][Full Text] [Related]
39. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
40. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]